RARE
UltragenyxNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.28B
P/E Ratio
—
EPS
$-5.83
Beta
0.25
52W High
$42.37
52W Low
$18.29
50-Day MA
$22.28
200-Day MA
$28.80
Dividend Yield
—
Profit Margin
-85.40%
Forward P/E
—
PEG Ratio
-0.24
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Fundamentals
| Revenue (TTM) | $673.00M |
| Gross Profit (TTM) | $-186.00M |
| EBITDA | $-500.00M |
| Operating Margin | -54.60% |
| Return on Equity | -608.00% |
| Return on Assets | -22.00% |
| Revenue/Share (TTM) | $6.83 |
| Book Value | $-0.83 |
| Price-to-Book | 247.70 |
| Price-to-Sales (TTM) | 3.38 |
| EV/Revenue | 2.323 |
| EV/EBITDA | -6.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 25.90% |
| Shares Outstanding | $98.32M |
| Float | $92.93M |
| % Insiders | 3.19% |
| % Institutions | 99.14% |
Analyst Ratings
Consensus ($52.45 target)
5
Strong Buy13
Buy2
HoldData last updated: 4/9/2026